166 related articles for article (PubMed ID: 12602762)
41. [Third generation selective estrogen receptor modulators: benefits beyond bone. II, endometrial action].
Calaf Alsina J; Coronado Martín PJ
Med Clin (Barc); 2013 Mar; 140(6):266-71. PubMed ID: 23276611
[TBL] [Abstract][Full Text] [Related]
42. Comparative effects of testosterone propionate, oestradiol benzoate, ICI 182,780, tamoxifen and raloxifene on hypothalamic differentiation in the female rat.
Pinilla L; Barreiro ML; Gonzalez LC; Tena-Sempere M; Aguilar E
J Endocrinol; 2002 Mar; 172(3):441-8. PubMed ID: 11874692
[TBL] [Abstract][Full Text] [Related]
43. "Non-hypercalcemic" analogs of 1alpha,25 dihydroxy vitamin D augment the induction of creatine kinase B by estrogen and selective estrogen receptor modulators (SERMS) in osteoblast-like cells and rat skeletal organs.
Somjen D; Waisman A; Weisman Y; Kaye AM
J Steroid Biochem Mol Biol; 2000; 72(1-2):79-88. PubMed ID: 10731641
[TBL] [Abstract][Full Text] [Related]
44. Selective estrogen receptor modulators for the chemoprevention of prostate cancer.
Steiner MS; Raghow S; Neubauer BL
Urology; 2001 Apr; 57(4 Suppl 1):68-72. PubMed ID: 11295598
[TBL] [Abstract][Full Text] [Related]
45. Clinical value of fulvestrant in breast cancer.
Gradishar WJ
Clin Breast Cancer; 2005 Apr; 6 Suppl 1():S4. PubMed ID: 15865848
[No Abstract] [Full Text] [Related]
46. Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens.
Margueron R; Duong V; Bonnet S; Escande A; Vignon F; Balaguer P; Cavaillès V
J Mol Endocrinol; 2004 Apr; 32(2):583-94. PubMed ID: 15072561
[TBL] [Abstract][Full Text] [Related]
47. The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.
McDonnell DP; Wardell SE
Curr Opin Pharmacol; 2010 Dec; 10(6):620-8. PubMed ID: 20926342
[TBL] [Abstract][Full Text] [Related]
48. Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels.
Yoneya T; Tsunenari T; Taniguchi K; Kanbe Y; Morikawa K; Yamada-Okabe H; Lee YH; Lee MH; Kwon LS
Oncol Rep; 2009 Mar; 21(3):747-55. PubMed ID: 19212635
[TBL] [Abstract][Full Text] [Related]
49.
Díaz M; Lobo F; Hernández D; Amesty Á; Valdés-Baizabal C; Canerina-Amaro A; Mesa-Herrera F; Soler K; Boto A; Marín R; Estévez-Braun A; Lahoz F
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069498
[TBL] [Abstract][Full Text] [Related]
50. The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells.
Freddie CT; Larsen SS; Bartholomaeussen M; Lykkesfeldt AE
Mol Cell Endocrinol; 2004 Apr; 219(1-2):27-36. PubMed ID: 15149724
[TBL] [Abstract][Full Text] [Related]
51. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.
Reiter R; Oh AS; Wellstein A; Riegel AT
Oncogene; 2004 Jan; 23(2):403-9. PubMed ID: 14691461
[TBL] [Abstract][Full Text] [Related]
52. SERMs attenuate estrogen-induced malignant transformation of human mammary epithelial cells by upregulating detoxification of oxidative metabolites.
Hemachandra LP; Patel H; Chandrasena RE; Choi J; Piyankarage SC; Wang S; Wang Y; Thayer EN; Scism RA; Michalsen BT; Xiong R; Siklos MI; Bolton JL; Thatcher GR
Cancer Prev Res (Phila); 2014 May; 7(5):505-15. PubMed ID: 24598415
[TBL] [Abstract][Full Text] [Related]
53. Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy.
Morris C; Wakeling A
Endocr Relat Cancer; 2002 Dec; 9(4):267-76. PubMed ID: 12542403
[TBL] [Abstract][Full Text] [Related]
54. Toxicity of antiestrogens.
Hirsimäki P; Aaltonen A; Mäntylä E
Breast J; 2002; 8(2):92-6. PubMed ID: 11896754
[TBL] [Abstract][Full Text] [Related]
55. A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer.
Rasmussen LM; Zaveri NT; Stenvang J; Peters RH; Lykkesfeldt AE
Breast Cancer Res Treat; 2007 Dec; 106(2):191-203. PubMed ID: 17268816
[TBL] [Abstract][Full Text] [Related]
56. [Selective estrogen receptor modulators (SERMs) in the practice].
Nagykálnai T
Magy Onkol; 2002; 46(2):165-75. PubMed ID: 12202896
[TBL] [Abstract][Full Text] [Related]
57. Tamoxifen prevention of breast cancer: an instance of the fingerpost.
Lippman SM; Brown PH
J Natl Cancer Inst; 1999 Nov; 91(21):1809-19. PubMed ID: 10547388
[No Abstract] [Full Text] [Related]
58. Influence of estrogens and antiestrogens on the expression of selected hormone-responsive genes.
Sismondi P; Biglia N; Ponzone R; Fuso L; Scafoglio C; Cicatiello L; Ravo M; Weisz A; Cimino D; Altobelli G; Friard O; De Bortoli M
Maturitas; 2007 May; 57(1):50-5. PubMed ID: 17395409
[TBL] [Abstract][Full Text] [Related]
59. Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium.
Jensen J; Kitlen JW; Briand P; Labrie F; Lykkesfeldt AE
J Steroid Biochem Mol Biol; 2003 Mar; 84(4):469-78. PubMed ID: 12732292
[TBL] [Abstract][Full Text] [Related]
60. [Selective estrogen receptors modulators (SERMs): biochemistry, pharmacology, and clinical use in gynecology].
Terán Dávila J; Teppa Garrán AD
Ginecol Obstet Mex; 2005 Aug; 73(8):424-35. PubMed ID: 16304968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]